Your patients’ health is your top priority. Better understand your patient’s genes and how they may impact their medications. Genelex, a leader in the field of molecular diagnostics and genetics laboratory testing for more than 30 years, in conjunction with a leading clinical decision support tool (CDST), may help you bring more effective medication management especially for high risk polypharmacy patients. The CDST was inspired by a healthcare provider who wanted to establish a more automated and precise medication management system to enhance patient care.

Genelex is a leader in precision medication management. A pioneer in DNA testing since 1987, Genelex now focuses exclusively on pharmacogenetic testing. Backed by a powerful combination of innovative analytics software, state-of art laboratory facilities, and expert staff, Genelex has a longstanding commitment to the prevention of dangerous and life-threatening adverse drug events (ADEs).

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.

Blueprint Genetics provides genetic diagnostics of rare diseases based on Next-Generation Sequencing (NGS). The professional genetic tests are targeted for hospitals and research groups. Blueprint Genetics aims to disrupt the market by decreasing the price level of genetic diagnostics significantly while increasing quality and adding clinical insight to the results statements. The tests are based on a novel NGS method called OS-Seq:tm: that was developed in the Stanford University. The product roadmap of the company covers a long list of diagnostics for different hereditary diseases. The currently available products cover relevant rare hereditary cardiovascular diseases, such as cardiomyopathies, arrhythmias and aorta diseases. The company is based in Helsinki, Finland and has an office also in Los Angeles, CA.